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ABSTRACT Most human adenoviruses encode two virus-
associated (VA) RNAs, VA RNAI and VA RNAII, that accu-
mulate to high levels in the cytoplasm of infected cells. The
function of VA RNAI in blocking the activation of the cellular
kinase PKR is well known, but the role of VA RNAII is obscure.
Herein we characterize and purify several human proteins
that interact preferentially with VA RNAII in Northwestern
blot assays. Two of these proteins were identified as RNA
helicase A and NF90, a component of the heterodimeric
nuclear factor of activated T cells (NFAT). They copurified
with the smaller NFAT subunit, NF45, which did not bind VA
RNAII, and with an unidentified protein, p97, which did bind
VA RNAII. Both RNA helicase A and NF90 contain two copies
of a double-stranded (ds) RNA binding motif and bind
strongly to dsRNA. NF90 interacts with RNAs in the following
order of affinity: dsRNA > VA RNAII > VA RNAI > single-
stranded RNA. Furthermore, VA RNAII is more effective than
VA RNAI as an inhibitor of RNA helicase activity. These data
identify RNA helicase A and NF90 as cellular proteins with an
affinity for dsRNA and other structured RNA molecules and
suggest that their functions are subject to regulation by RNA
ligands including VA RNAII.
RNA molecules fulfill numerous structural, catalytic and
regulatory roles in the cell. The virus associated (VA) RNAs
are short (;160 nucleotide), highly structured but single-
stranded molecules that are actively synthesized by cellular
RNA polymerase III. They accumulate to high concentrations
in the cytoplasm of adenovirus-infected cells, predominantly
during the late phase of virus infection (1). Most human
adenovirus serotypes contain two VA RNA genes, encoding
VA RNAI and VA RNAII, whereas the remainder carry a
single gene of the VA RNAI type (2). VA RNAI counteracts
a cellular antiviral defense mechanism that would otherwise
lead to the shut-off of protein synthesis in infected cells. In
particular, VA RNAI blocks the activation by double-stranded
(ds) RNA of the interferon-inducible protein kinase PKR
(previously known as DAI, P1, p68, or PK-ds) (3–6). Activated
PKR inhibits protein synthesis by phosphorylating initiation
factor eIF2 (7). Thus, VA RNAI maintains the functional
integrity of the translation system in adenovirus-infected cells.
It can also increase expression of proteins from transfected
genes in uninfected cells (8, 9).
The function of VA RNAII is unclear. Its limited ability to
block PKR activation (10, 11) argues against a role similar to
that of VA RNAI, especially in light of its lesser accumulation
in infected cells (12). Furthermore, a mutant virus that fails to
produce VA RNAII grows as well as wild type in culture (13).
These data are compatible with the view that VA RNAII does
not play an important part in the adenovirus life cycle, but
several lines of evidence favor the opposite point of view. (i)
Although the VA RNAII2 mutant virus is not defective in virus
yield, the VA RNAI2yVA RNAII2 double mutant grows about
10-fold less well than the VA RNAI2 mutant (13–16). More-
over, virus production is delayed during the first 3 days of
infection with the VA RNAII2 mutant (13). (ii) VA RNAII is
abundantly synthesized in infected cells (12), reaching about
107 molecules per cell (even though this is only about 10% of
the level of VA RNAI). (iii) Although about 20% of human
adenoviruses lack a VA RNAII gene, and some even seem to
have lost it during recent evolution, the great majority of
human serotypes (;80%) possess a VA RNAII gene (2). (iv)
Finally, and most compelling, the VA RNAII genes are at least
as highly conserved as other VA RNA genes in sequence, and
the secondary structures of their transcripts are also similar
(2).
Such observations make it likely that the VA RNAII gene is
biologically significant but shed little light on the process(es)
in which it is involved. To address the possible biological
function(s) of VA RNAII, we have investigated cellular pro-
teins that interact with it. By using a Northwestern blotting
assay, we detected eight proteins that bind preferentially to VA
RNAII. Two of them were partially purified and identified by
protein sequencing and antibody reactivity: one is RNA heli-
case A and the other is the large subunit (NF90) of the nuclear
factor of activated T cells (NFAT or NF90yNF45). Their RNA
binding properties were characterized, and VA RNAII was
shown to inhibit RNA helicase A activity preferentially.
MATERIALS AND METHODS
Cells and Cell Extracts. Human 293 cells (17), a line of
adenovirus-transformed embryonic kidney cells, were grown
in suspension culture. Cell extracts were prepared by Dounce
homogenization and fractionated by standard procedures (18–
20) to give nuclear extract (NE), 10,000 3 g supernatant and
pellet fractions (S10 and P10, respectively), and 100,000 3 g
supernatant and pellet fractions (S100 and P100, respectively),
as diagrammed in Fig. 1A.
Northwestern Blotting and Immunoblotting. Proteins were
separated by SDSyPAGE (21) and then transferred to nitro-
cellulose membranes (Schleicher & Schuell BA85 membrane,
0.45-mm pore size) by electroblotting. For Northwestern blot
analysis, membrane-bound proteins were subjected to dena-
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turation and renaturation by sequential incubation with 6 M,
3 M, 1.5 M, 0.75 M, and 0.375 M guanidine hydrochloride in
buffer C (20 mM HepeszNaOH, pH 7.6y3 mM MgCl2y40 mM
KCly10 mM 2-mercaptoethanol). Membranes were then
washed with buffer C, blocked with a 2% solution of Carnation
nonfat dry milk in buffer C, and rinsed with buffer C contain-
ing 200 mM KCl. For probing with radiolabeled RNA, mem-
branes were incubated for 1 h with 32P-labeled RNA (5 to 10 3
104 Cerenkov counts per min per ml) in buffer C containing
200 mM KCl, 0.1% Triton X-100, and 500 mg of heparin per
ml. After washing with buffer C containing 200 mM KCl and
0.01% Triton X-100, the membranes were air-dried and ex-
posed to film with enhancer screens for autoradiography or
BAS 2000 Fuji Phosphoimager for imaging. For immunoblots,
membranes were blocked with 5% Carnation nonfat dry milk
in TBST (20 mM TriszHCl, pH 7.6y150 mM NaCly0.1% Tween
20) and then with 5% BSA in TBST. The membranes were
probed with primary antibody (1:1,000 dilution) in 5% BSAy
TBST for 1 h, rinsed with TBST, reblocked with 2% BSAy
TBST, and then incubated with secondary antibody for 1 h.
After washing with TBST, bound antibody was detected by
enhanced chemiluminescence. Antibodies against human
RNA helicase A were provided by Chee-Gun Lee (Sloan–
Kettering Institute, New York) and against NF90 and NF45 by
Peter Kao (Stanford University).
Purification of VA RNA Binding Proteins. All procedures
were carried out at 0–4°C with buffers containing 20% glyc-
erol, 1 mg of leupeptin per ml, 1 mg of aprotinin per ml, 1 mg
of pepstatin A per ml, 0.2 mM phenylmethylsulfonyl f luoride,
and 0.5 mM DTT. The S10 fraction of 293 cells was loaded
onto a column of poly(I)zpoly(C)-agarose resin (Pharmacia
Biotech) equilibrated with buffer A (20 mM HepeszNaOH, pH
7.6y3 mM MgCl2y200 mM KCl). The column was washed with
buffer A containing 0.01% Triton X-100 and material was
eluted with a linear gradient of 0.25–2 M NaCl in the same
buffer.
Protein Sequence Analysis. Peptide sequences were ob-
tained from proteins separated by SDSyPAGE as described
(22), except that the Tween concentration was 0.05%. Briefly,
the proteins (3–10 pmol) were located by staining with Coo-
massie blue G (Sigma), excised, and digested in gel slices with
Achromobacter protease I (Wako) for 20 h at 30°C. Peptides
were separated on a C18 column and sequenced with an
Applied Biosystems model 494 instrument. Initial yields aver-
aged 3 pmol (range, 1.1–5.6 pmol).
Preparation of 32P-Labeled RNAs. VA RNA probes were
transcribed from DraI-linearized plasmids pT7VA2I and
pT7VA2II (10) by using T7 RNA polymerase in the presence
of [a-32P]UTP (ICN Radiochemicals) and purified by sequen-
tial electrophoresis through denaturing and native polyacryl-
amide gels (10, 23). dsRNA probe of 104 bp was prepared by
transcription of pBSII KS1 (Stratagene), with T3 and T7 RNA
polymerases (24). After annealing and removal of single-
stranded (ss) RNA by digestion with RNases A and T1, the
dsRNA was purified by electrophoresis through a native 10%
polyacrylamide gel. dsRNA substrates for RNA helicase assays
were prepared in the same way except that the T7 RNA
polymerase transcription template was linearized with EcoRI
instead of PvuII, and single-stranded ends were not trimmed
by RNase digestion. ssRNA was prepared by transcription of
EagI-linearized pBSII KS1 with T3 RNA polymerase and
purification through two gels as described above.
Binding of RNAs to NF90. NF90 protein was adsorbed from
the S10 fraction of 293 cells onto protein A-Sepharose beads
(Pharmacia) carrying rabbit polyclonal anti-NF90 antibodies
(25). The NF90-containing Sepharose beads were washed six
times with IP buffer (20 mM HepeszKOH, pH 7.9y0.5 mM
DTTy0.2 mM EDTAy50 mM KCly20% glyceroly0.01% Non-
idet P-40y100 units of aprotinin per mly1 mM phenylmethyl-
sulfonyl f luoride), equilibrated with buffer B (26), then incu-
bated with RNA probe (5 3 104 cpm) in buffer B containing
100 mg of calf liver tRNA per ml and 1,000 units of RNASIN
(Promega) per ml. for 5 min at 30°C and a further 25 min at
4°C. The beads were washed four times with buffer B con-
taining 10 mg of calf liver tRNA per ml, and the binding of
RNA to immobilized NF90 was monitored by Cerenkov
counting.
Helicase Assay and Immunodepletion. The RNA helicase
assay was carried out as described (27) by using 2.5 to 5 3 104
cpm of 32P-labeled dsRNA substrate in each reaction. The
source of enzyme was fraction 24 of the poly(I)zpoly(C)-
agarose column (dialyzed against buffer A containing 20%
glycerol) or purified human RNA helicase A (kindly provided
by Chee-Gun Lee). For immunodepletion, column fraction 24
was treated with protein A-Sepharose beads carrying antibody
directed against human RNA helicase A (28) or an irrelevant
rabbit preimmune serum as a control by using a slight modi-
fication of the procedure used for NF90 immobilization. The
supernatants were assayed directly for RNA helicase or sub-
jected to further immunodepletion and then assayed.
RESULTS
VA RNAII interacts with cellular proteins. The function of VA
RNAI was revealed through the analysis of the protein syn-
FIG. 1. Detection and subcellular localization of VA RNAII bind-
ing proteins. (A) Fractionation scheme showing the distribution of VA
RNAII binding proteins. (B) Autoradiogram of a Northwestern blot,
containing proteins from the indicated 293 cell fractions, probed with
32P-labeled VA RNAII. Lane M contains marker proteins whose
molecular masses are indicated in kDa.
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thesis deficiency associated with the VA RNAI-negative viral
genotype (1, 5, 13, 29). In the absence of a clear phenotype
resulting from the lack of VA RNAII, at least in cultured cells,
we examined its interaction with cellular proteins as an alter-
native strategy to approach the role(s) of this RNA. Cytoplas-
mic and nuclear fractions were prepared from human 293 cells
and the cytoplasmic extract was further fractionated by cen-
trifugation to give S10, P10, S100, and P100 fractions (Fig. 1A).
These fractions were subjected to analysis by the Northwestern
blotting technique: proteins separated in an SDSypolyacryl-
amide gel were transferred to nitrocellulose membrane and
probed with 32P-labeled VA RNAII.
About eight bands were detected in the various fractions
(Fig. 1B). The most prominent and reproducible of these
migrated with apparent molecular masses of 120, 97, and 84
kDa, corresponding to proteins designated p120, p97, and p84,
respectively. The p120 band was detected in the cytosolic
fractions P100 and S10 (lanes 1 and 4) but not in the P10, S100,
or nuclear extract fractions (Fig. 1B, lanes 2, 3, and 5), implying
that p120 may be ribosome-associated. The p97 and p84 bands
were present in the same two cytosol fractions (Fig. 1B, lanes
1 and 4) and in the nuclear extract fraction (Fig. 1B, lane 5),
suggesting that these proteins either shuttle between the
nucleus and cytoplasm or leach out of nuclei during fraction-
ation. A weak band comigrating with p84 was also seen in the
S100 fraction (Fig. 1B, lane 3). Additional bands included p94,
which was seen only in the P100 fraction (Fig. 1B, lane 1); p75,
the only band detected in the P10 fraction (Fig. 1B, lane 2); p55
and p35, shared by the nuclear extract and S10 fractions (Fig.
1B, lanes 5 and 4); and p50, common to the S10 and S100
fractions (Fig. 1B, lanes 4 and 3). The distribution of these VA
RNAII- binding proteins is depicted in Fig. 1A.
To address the specificity of these interactions, we probed
with VA RNAI. The same bands were detected but the
intensity of the signal was greatly attenuated, indicative of
preferential binding to VA RNAII (data not shown). Similar
proteins were also detected in extracts of human KB cells,
although the p97 band was notably stronger than in 293 cell
extracts (data not shown). The strength of the p50 signal, which
probably corresponds to the La protein (30, 31) was variable
with both probes, but the interactions with p120, p97, and p84
were reproducible and these proteins bound preferentially to
VA RNAII rather than VA RNAI.
Identification of p120, p84, and a Copurifying Protein, p42.
The 293 cell S10 fraction was chosen for protein purification
because it contains the three prominent VA RNAII-binding
proteins, p120, p97, and p84 and because the bulk of this RNA
is cytoplasmic (12). These bands were all detected when
Northwestern blots were probed with radiolabeled dsRNA
(data not shown), suggesting that chromatography on
poly(I)zpoly(C)-agarose might be a useful purification step.
Indeed, elution with a salt gradient gave a remarkably good
FIG. 2. Purification of VA RNA binding proteins. (A) Copurifi-
cation of p120, p84, and p42 through chromatography of the 293 cell
S10 fraction over poly(I)zpoly(C)-agarose. Eluted proteins were ex-
amined by SDSygel electrophoresis and staining with Coomassie
brilliant blue. Lane L contains a sample of the S10 fraction loaded on
the column. (B) Detection of VA RNAII binding activities in column
fractions by Northwestern blotting. Positions of the p120, p97, p84, and
p42 bands are indicated with dots in A. Lanes M, M1, and M2 contain
marker proteins with molecular masses in kDa.
FIG. 3. Protein identification. Amino acid sequences of peptides
from p120 (A), p84 (B), and p42 (C) are matched with published
sequences from human RNA helicase A, NF90, and NF45, respec-
tively. The numbers indicate N-terminal and C-terminal amino acid
positions for the published sequences. Identical residues are under-
lined; uppercase type denotes a clear sequencing signal; lowercase type
represents amino acids that gave less distinctive signals or were not
readable. A mismatch between p120 and RNA helicase A is indicated
by boldface type. (D) Immunoblot analysis with antibodies directed
against human RNA helicase A, NF90, or NF45. Proteins from a
poly(I)zpoly(C)-agarose fraction were resolved in an SDSy
polyacrylamide gel and then examined by staining with Coomassie
brilliant blue or by Western blot analysis as indicated.
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one-step purification of the three proteins. As shown in the
stained gel of Fig. 2A, proteins of the expected mobilities were
present in fractions 20–29 (corresponding to about 0.6–1 M
NaCl). The only other visible band, p42, coeluted with the peak
of p120, p97, and p84. The latter three proteins were all
detected when these fractions were analyzed for VA RNAII-
binding activities by Northwestern blotting, but p42 was not
detected (Fig. 2B).
Proteins from a peak fraction were resolved by gel electro-
phoresis and subjected to peptide sequencing procedures.
Data were obtained for p120, p84, and p42 and were compared
with database information. Three peptide sequences from
p120 matched human RNA helicase A (28) with a single
discrepancy at residue 183, where asparagine was found in-
stead of isoleucine (Fig. 3A). Asparagine is also reported at this
position in the bovine homologue of human RNA helicase A
(32). Four peptides from p84 matched the human protein
NF90 (Fig. 3B), a component of the heterodimeric DNA-
binding protein NF90yNF45 (33, 34). Two peptide sequences
derived from p42 matched the NF45 sequence (Fig. 3C).
Because p42 coeluted precisely with p84 from the
poly(I)zpoly(C) column but did not bind RNA in Northwestern
analyses, we presume that p42 copurified through its interac-
tion with p84.
To verify the identities of these proteins, they were resolved
in an SDSypolyacrylamide gel, transferred to nitrocellulose
membrane, and probed with antibodies to human RNA heli-
case A, NF90, and NF45. Comparison with the stained proteins
showed that the antibodies specifically recognized p120, p84,
and p42, respectively (Fig. 3D). Thus, these results identify the
cellular VA RNA-binding proteins p120, p84, and the copu-
rifying p42, with human RNA helicase A and the NF90–NF45
complex. Accordingly, the proteins will be referred to by their
original names in the balance of this report.
Specificity of RNA Binding to Immobilized NF90 (p84).
NF90, in a complex with NF45, binds to the NFAT DNA
recognition element but has not previously been shown to bind
RNA. To examine the RNA-binding activity of NF90, the
protein was adsorbed from 293 cell S10 onto beads via
anti-NF90 antibody. The beads were exposed to various 32P-
labeled RNAs, unbound probe was removed, and bound RNA
was monitored by assaying the retained radioactivity. Fig. 4
shows that NF90 efficiently bound dsRNA, whereas ssRNA
gave a signal that was barely above background obtained in the
absence of NF90. VA RNAII also bound efficiently, albeit to
a lesser extent than dsRNA, whereas VA RNAI bound poorly.
Similar results were obtained with chromatographically puri-
fied NF90 (data not shown). Thus, NF90 is able to bind dsRNA
and highly structured ssRNAs such as VA RNAII; strikingly, in
keeping with the results from Northwestern blotting, NF90
binds VA RNAII significantly better than VA RNAI even
though both species have a high degree of secondary structure.
The Northwestern blotting data make it likely that NF45 is not
required for VA RNA binding to NF90.
Helicase Activity Is Inhibited by VA RNA. To determine
whether the activity of RNA helicase A can be regulated by
FIG. 4. RNA binding to NF90 (p84). Sepharose beads carrying
NF90 were exposed to 32P-labeled dsRNA, VA RNAI (Ad2 VAI), VA
RNAII (Ad2 VAII), or ssRNA. The binding of RNA to immobilized
NF90 was measured by the retention of radioactivity (cpm) on the
beads. Data are averages of triplicate assays. Antibody was omitted for
the control, which represents the average of single assays with each of
the RNA probes.
FIG. 5. RNA helicase activity is associated with p120. (A) 32P-
labeled dsRNA substrate was incubated alone (lane 3) or with
increasing amounts of fraction 24 from poly(I)zpoly(C)-agarose chro-
matography (0.1, 0.3, and 0.5 ml for lanes 4–6, respectively). Lanes 1
and 2 contain untreated and boiled dsRNA, respectively. (B) RNA
helicase assays were conducted in the absence (lane 1) or presence
(lane 2) of fraction 24, with fraction 24 that had been depleted by
treatment with antibody to human RNA helicase A (lanes 3, 5, and 7),
or with mock-depleted (lanes 4, 6, and 8) fraction 24. Three sequential
cycles of immunodepletion were conducted as indicated. The positions
of dsRNA and ssRNA are marked.
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VA RNA, we first established that p120 purified by
poly(I)zpoly(C)-agarose chromatography possessed helicase
activity. Fractions containing p120 were incubated with radio-
labeled dsRNA and the reaction products were analyzed by gel
electrophoresis to detect the conversion of dsRNA to ssRNA
(Fig. 5A, lanes 1 and 2). Incubation with increasing volumes of
fraction 24 led to a progressive decrease in the amount of
dsRNA and concomitant appearance of ssRNA (Fig. 5A, lanes
3–6). Evidence that this is due to RNA helicase A was adduced
from immunodepletion experiments (Fig. 5B). In the presence
of fraction 24, dsRNA was converted to ssRNA (Fig. 5B, lanes
1 and 2). Serial immunodepletion with specific antibody
progressively diminished the helicase activity of fraction 24
(Fig. 5B, lanes 3, 5, and 7), whereas control antibodies had no
effect (Fig. 5B, lanes 4, 6, and 8), suggesting that RNA helicase
A is the only RNA helicase active in the column fraction. As
reported for human RNA helicase A (27), the RNA helicase
activity of p120 is ATP-dependent: no unwinding of dsRNA
occurred in the absence of ATP (Fig. 6A, lanes 4 and 5).
Both VA RNAs reduced the unwinding of dsRNA (Fig. 6A,
lanes 6–10). When tested at the same concentration, VA
RNAII was approximately 3-fold more inhibitory toward he-
licase activity than VA RNAI. To verify that these results are
not influenced by the presence of NF90yNF45 or other
proteins in the poly(I)zpoly(C)-agarose column fraction, the
experiment was repeated with highly purified human RNA
helicase A. Again, the VA RNAs reduced helicase activity and
VA RNAII was approximately 3-fold more inhibitory than VA
RNAI (Fig. 6B). It is important to note that the VA RNAs used
in this study were purified through a procedure that is docu-
mented to remove dsRNA contaminants (23) and were free of
dsRNA in PKR assays (data not shown). We conclude that VA
RNA can inhibit the activity of RNA helicase A.
DISCUSSION
We have identified two cellular proteins, RNA helicase A and
the NF90 component of NFAT, that can bind dsRNA and
highly structured ssRNAs such as adenovirus VA RNAs. Both
of these proteins are members of a growing family of proteins
that contain the dsRNA-binding motif (dsRBM), and—like
PKR—they both contain two tandem copies of the repeat (34,
35). This protein family includes PKR, Drosophila staufen, and
Escherichia coli RNase III, for all of which convincing data
exist demonstrating that the dsRBM is directly engaged in
RNA binding (36–38), as well as other proteins that are known
to interact with RNA (38). At present, it is an unverified but
plausible assumption that the dsRBM is responsible for the
observed interactions of RNA helicase A and NF90 with
structured RNAs. If this proves to be the case, the results
presented herein imply that the dsRBM does not bind struc-
tured RNAs indiscriminately. Both of these proteins appear to
interact more strongly with VA RNAII than VA RNAI (Figs.
4 and 6), whereas PKR exhibits relatively stronger interactions
with VA RNAI than VA RNAII (1, 10). Although the struc-
tures of two dsRBMs have been solved by NMR (38, 39),
further analyses of the interactions of dsRBMs with RNAs will
be required to understand the basis of the specificity.
Both RNA helicase A and NF90 participate in pivotal
cellular control processes. RNA helicase A plays a central role
in transcriptional regulation. It belongs to the DEAH sub-
group of the DEAD box (DEAHyDexH) family of helicases
and unwinds DNA as well as dsRNA (28, 40). Although RNA
helicase A was first reported as a helicase that catalytically
translocates in the 39 to 59 direction and did not unwind
59-tailed DNA substrates significantly, our study shows that it
can unwind 59-tailed dsRNA substrates (Figs. 5 and 6). Its
Drosophila homologue, the Maleless protein, plays an essential
role in dosage compensation by up-regulating X chromosome
transcription in the early stages of male fly development (28,
40). In human cells, it is associated with RNA polymerase II
(pol II) and the cAMP responsive factor (CREB)-binding
protein (CBPyp300) and functionally cooperates with this
transcriptional coactivator to stimulate transcription (41). The
NTPaseyhelicase activities of RNA helicase A and Maleless
are essential for their transcriptional functions. Additional
roles for RNA helicase A (for example, in replication or
translation) have not been ruled out, and a posttranscriptional
role in RNA export from the nucleus has been inferred (42).
RNA helicase A is normally seen in the cell nucleus, but it
appears to shuttle between the nucleus and cytoplasm in
simian retrovirus-infected cells. This property may account for
our detection of the helicase in the cytoplasmic fraction (Fig.
1).
Less is known about the functions of the NF90yNF45
complex. It was originally purified from T cells by virtue of its
ability to bind to a DNA element, the ARRE, from the human
interleukin 2 promoter (33, 34). Like other, unrelated, mem-
bers of the NFAT family of transcriptional activators, its DNA
binding activity was stimulated by ionomycin and phorbol
12-myristate 13-acetate, factors that stimulate T cell activation.
FIG. 6. Inhibition of RNA helicase activity by VA RNAs. (A)
Helicase assays with poly (I)zpoly (C)-agarose fraction 24. Lane 6
contained a standard reaction. VA RNAI or VA RNAII were present
in the reactions displayed in lanes 7–10 at 7.6 ngyml (lanes 7 and 9) and
22.8 ngyml (lanes 8 and 10). Control reactions lacking fraction 24 or
ATP (lanes 4 and 5) were also conducted. Lane 3 contains boiled
dsRNA substrate. (B) Helicase assays with purified human RNA
helicase A. Lane 4 contained a standard reaction. VA RNAI or VA
RNAII were present at 3.8 ngyml (lanes 5 and 7) and 11.4 ngyml (lanes
6 and 8). RNA helicase was omitted from the reaction of lane 3. Lanes
1 and 2 of A and B contain 32P-labeled dsRNA and ssRNA markers,
and their positions are indicated.
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That NF90 and NF45 play a role in transcription is suggested
by immunodepletion experiments (33). Unlike other members
of the NFAT family, however, the expression of NF90yNF45
is not limited to immune cells (34), raising the possibility that
it participates in the transcription of a variety of genes. Despite
their appearance in both the nuclear and cytoplasmic fractions
(Fig. 1), NF90 and NF45 are predominantly detected in the
nuclei by immunofluorescence. NF90 shares extensive homol-
ogy with several proteins, including Xenopus dsRNA binding
proteins (43), the mouse spermatid perinuclear RNA binding
protein Spnr (44), and especially human M-phase phospho-
protein 4 (45). The latter is present throughout the cell cycle
but is phosphorylated specifically during mitosis, suggestive of
a cell-cycle-dependent function.
What is the significance of the interactions between these
proteins and their RNA ligands? In the case of PKR, dsRNA
serves as an activator of the latent kinase, whereas VA RNAI
opposes the enzyme’s activation, thereby neutralizing one
aspect of the cellular antiviral response. By analogy, VA RNAII
may promote viral infection by regulating the properties of
RNA helicase A and NF90. Support for this idea comes from
the observations that VA RNAII binds selectively to NF90 and
that it (and, to a lesser degree, VA RNAI) inhibits the
dsRNA-unwinding action of RNA helicase A. Because these
three proteins appear to interact with one another (I. Fierro-
Monti, L. Parker, and M.B.M., unpublished results), it is
tempting to speculate that they participate in a concerted
regulatory mechanism that is influenced by one or both of the
VA RNAs. Moreover, our data raise the possibility that other
structured cellular and viral RNAs, such as the Alu and Ro
RNAs and EBERs of Epstein–Barr virus, for example, may
also exert control over cell functions through interactions with
these RNA-binding proteins.
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